A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms

Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring

(2014) Jianxiang Chi et al.   ANNALS OF HEMATOLOGY

Two faces of ET: CALR and JAK2

(2014) M. P. Chao et al.   BLOOD

Calreticulin mutations in Chinese with primary myelofibrosis

(2014) B. Li et al.   HAEMATOLOGICA

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

CALR mutations and a new diagnostic algorithm for MPN

(2014) Ayalew Tefferi et al.   Nature Reviews Clinical Oncology

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis

(2013) J Chi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA